AtriCure expands beyond AF to all open-heart surgeries, with 2027 catalysts, strong profitability, and growth. Click for more on ATRC stock.
AtriCure (ATRC) delivered earnings and revenue surprises of +1,600.00% and +2.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
AtriCure’s fair value price target has shifted from about US$51.67 to about US$54.89, which reflects modest fine tuning in analyst models rather than a wholesale reset. Recent research ties these adjustments to how analysts balance new procedural drivers such as the STS Quality Metric and future BoX-NoAF POAF data against ongoing clinical and execution risks, as well as the tighter cluster of targets around the current valuation range. Read on to see how to track this evolving analyst...
Detailed price information for Atricure Inc (ATRC-Q) from The Globe and Mail including charting and trades.
AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales. The question now is how that recent performance lines up with the revenue the business is actually generating. The share price has gained 73.5% over the past year, which puts added weight on whether the current valuation can be explained by its sales base. The company’s focus on cardiac surgical devices means future growth in procedure...
AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers. Recent trading has been strong for AtriCure, with a 30-day share price return of 24.84% and a 90-day share price return of 101.36%. This feeds into a year-to-date share price gain of 54.75% and a 1-year total shareholder return of 73.48%, even though the 5-year total shareholder return is down 12.62%. Spot fresh...
Salvatore Privitera, Chief Technical Officer, on September 23, 2026, sold 4,519 shares in Atricure (
Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.
Detailed price information for Atricure Inc (ATRC-Q) from The Globe and Mail including charting and trades.
AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Privitera Salvatore, Chief Technical Officer, on September 02, 2026, sold 7,763 shares in Atricure (
AtriCure (ATRC) has an average rating of buy and mean price target of $51.67, according to analysts
Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimbursement and regulatory support offer further growth. Atrial Fibrillation Treatment Devices Market Atrial Fibrillation Treatment Devices Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Devices Market by Type of Device, Type of Technology, End
MASON, Ohio, August 25, 2026--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.
This is the newest page. Registered accounts read further back.